OXIGENE (OXGN) Rips After Geting SPA From FDA for ZYBRESTAT Phase 3

September 17, 2012 4:35 PM EDT Send to a Friend
OXIGENE (Nasdaq: OXGN) shares are popping higher in late trading Monday after announcing it came to a Special Protocol Assessment (SPA) with the FDA for its Phase 3 clinical trial (FACT 2) of ZYBRESTAT for the treatment of anaplastic thyroid cancer (ATC).

Shares are up over 18 percent.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Momentum Movers

Add Your Comment